XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.1.u1

Segments (Tables)

3 Months Ended

Mar. 31, 2024

Summary of Segment Profit

a. Segment information:

		Three months ended March 31,
		2024
		United States				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	1,725			$	1,272			$	597
Gross profit			858				738				297
R&D expenses			154				56				28
S&M expenses			261				194				118
G&A expenses			93				65				35
Other income			1				1					§
Segment profit		$	350			$	423			$	117

§ Represents an amount less than $0.5 million.

		Three months ended March 31,
		2023
		United States				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	1,677			$	1,184			$	581
Gross profit			789				655				285
R&D expenses			149				53				27
S&M expenses			207				187				113
G&A expenses			95				70				38
Other income				§				§			(1	)
Segment profit		$	338			$	345			$	108

§ Represents an amount less than $0.5 million.

The following table presents a reconciliation of Teva’s segment profits to its consolidated operating income (loss) and to consolidated income (loss) before income taxes for the three months ended March 31, 2024 and 2023:

		Three months ended March 31,
		2024				2023
		(U.S. $ in millions)
United States profit		$	350			$	338
Europe profit			423				345
International Markets profit			117				108
Total reportable segments profit			890				791
Profit (loss) of other activities			2				(6	)
Total segments profit			892				785
Amounts not allocated to segments:
Amortization			152				165
Other assets impairments, restructuring and other items *			673				110
Intangible assets impairments			80				178
Legal settlements and loss contingencies			106				233
Other unallocated amounts			99				112
Consolidated operating income (loss) *			(218	)			(13	)
Financial expenses, net			250				260
Consolidated income (loss) before income taxes *		$	(467	)		$	(272	)

* The data presented for the prior period have been revised to reflect a revision in the presentation of these items in the consolidated financial statements. For additional information see note 1c.

Schedule of Net Sales by Product Line

The following tables present revenues by major products and activities for the three months ended March 31, 2024 and 2023:

United States		Three months ended March 31,
		2024				2023
		(U.S. $ in millions)
Generic products		$	808			$	747
AJOVY®			45				46
AUSTEDO			282				170
BENDEKA® and TREANDA®			46				62
COPAXONE			30				71
Anda			381				424
Other			133				158
Total		$	1,725			$	1,677

Europe		Three months ended March 31,
		2024				2023
		(U.S. $ in millions)
Generic products		$	1,004			$	932
AJOVY			51				36
COPAXONE			57				59
Respiratory products			66				68
Other			94				89
Total		$	1,272			$	1,184

International markets		Three months ended March 31,
		2024				2023
		(U.S. $ in millions)
Generic products		$	477			$	477
AJOVY			17				13
COPAXONE			12				17
Other			91				74
Total		$	597			$	581

X

- Definition

Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration